Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The SENTINEL 1 Study: An Observational, Non-Interventional Study in the United States to Characterize Respiratory Syncytial Virus Hospitalizations Among Infants Born at 29 to 35 Weeks Gestational Age Not Receiving Immunoprophylaxis

NCT02273882 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02273882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02273882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The SENTINEL 1 Study: An Observational, Non-Interventional Study in the United States to Characterize Respiratory Syncytial Virus Hospitalizations Among Infants Born at 29 to 35 Weeks Gestational Age Not Receiving Immunoprophylaxis
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
November 17, 2014
Completion date
August 19, 2016
Enrollment
497 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus hospitalizations